About this Research Topic
Breast cancer heterogeneity is being defined more precisely at the molecular level. This provides an unprecedented opportunity to understand how differential expression of steroid receptors, p53, Rb and other tumor suppressor proteins and interaction/crosstalk among them drive different subtypes of breast cancer. How do steroid receptors influence tumor suppressor pathways and vice-versa in breast cancer? What are the underlying mechanisms of this interaction? How do mutations in these proteins affect the interaction and downstream signaling? How does gain-of-oncogenic function mutations in tumor suppressor proteins impact this crosstalk? How can this information be exploited for the development of novel therapeutic strategies based on molecular stratification and novel biomarkers?
This Research Topic thus welcomes Original Research and Review articles addressing, but not limited to, the following themes:
-Role of estrogen receptors alpha and beta (ERα, ERβ) progesterone receptor (PR), glucocorticoid receptor (GR), androgen receptor (AR), and Vitamin D receptor (VDR) in breast cancer
-Functions of wild type (WT) and mutant p53, Rb and other tumor suppressor proteins in different molecular subtypes of breast cancer
-Major pathways (involved in tumor growth, invasion, and metastasis) impacted by the interaction/crosstalk between different steroid receptors, and WT and mutant tumor suppressor proteins
-Role of p53 context (WT versus mutant) in determining opposite functions of the same steroid receptor
-Exploiting signaling crosstalk to develop novel personalized therapies, for patients with breast cancer
-Importance of steroid hormone receptors and p53 in designing prospective clinical studies on breast cancer
-Regulation of tumor cell metabolism by steroid receptor-tumor suppressor signaling crosstalk
-Estrogen receptors, p53 and tumor micro/immune environment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.